EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs - Test2 - elhamkhani - TriplyDB

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

http://www.wikidata.org/entity/Q34110066

about

Advances in rheumatology: new targeted therapeutics Subcutaneous or intramuscular methotrexate for rheumatoid arthritis Fish oil supplements for rheumatoid arthritis Methotrexate for ankylosing spondylitis Folic Acid Supplementation for Rheumatoid Arthritis Patients on Methotrexate: The Good Gets Better Interventions for periodontal disease in people with rheumatoid arthritis Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis Etanercept for the treatment of rheumatoid arthritis Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidity Pain management for inflammatory arthritis and gastrointestinal or liver comorbidity Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)Combination therapy for pain management in inflammatory arthritis 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications Rheumatoid Arthritis: The Stride from Research to Clinical Practice The specialist physician's approach to rheumatoid arthritis in South Africa Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis Access to an optimal treatment. Current situation Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review Advances in the treatment of polyarticular juvenile idiopathic arthritis Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Personalized medicine in rheumatology 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative Leukoencephalopathy due to oral methotrexate The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis

P2860

Q21093257-07A21155-5A81-44CD-8C9F-C0496A030FD2 Q24187565-78A98989-6931-40B5-BB9F-FBDDCABD8D61 Q24197686-C13FE3E4-3398-4698-8375-30C1D0136B4D Q24200564-09E5AF26-90EE-4193-841E-093ABA714D6C Q24200922-60238376-644A-43B5-94FE-A2F219B4CBB2 Q24200961-FB011DDA-7577-4DF8-9FE4-4097AA333F34 Q24202055-7DF16BF8-8DC0-465E-BC03-BC36956F6B41 Q24202751-4929E30E-1695-4CE8-9C56-B78A1C9C5D42 Q24203871-EDA45460-6042-400B-91DB-AC0E08857A8A Q24235302-5BAB8290-EB23-4347-9302-087577634EA5 Q24235846-AFDA49E5-F51B-4936-852C-694406CF9D44 Q24236350-2B81C385-1C2F-4A1A-A936-81865614236C Q24603648-998C6DF8-F0FB-48E7-B228-FF18E305632B Q24631295-27956050-AAF2-459A-A36A-3DEA34917FDD Q26738960-199B7E63-0735-49D9-9E98-F316CAC80EBC Q26747512-A5775872-B1AC-4FBC-810D-94B6871322F8 Q26765122-01EBCC43-E0B8-47C2-9E2A-B012D389FD6F Q26769021-373B0903-7C33-43B6-AFD6-67C0CD6DA80D Q26774874-64E696B0-5A71-4C9F-BCC7-9D36675FC256 Q26781712-79DC3096-1674-4653-968D-6F248E65A7EB Q26784247-F83AAB4C-D54B-4ED0-B6EE-D76EC223237F Q26799036-86142D8B-433C-490D-9E9A-5507B373B798 Q26799304-F80F07AB-4D67-462C-B8D4-31258CC4D1E2 Q26824859-3E34F96D-016F-48A2-8168-047A5C2039A3 Q26828418-E9B7C94E-02FF-4B2C-85A4-E7DE74C82AA7 Q26852235-04636D94-74B5-44E9-9AEE-C0E72F95E0BA Q26859134-5076CE6A-C340-4C90-A644-320B79CA2FFB Q26859493-B9C46092-46E8-456C-B440-FE785C9CBCBA Q26995202-2C55CB8D-17B9-4108-A22B-C3A92577B465 Q27001017-D8630B6B-DAB4-4883-9BBB-FFDA615A3410 Q27010957-22DEBFB1-DC69-4849-8D6D-E238EAF8EFB7 Q27012134-DFA7D6FC-D179-4783-B158-08B2533A7306 Q27691388-C2BEEB0F-0DF1-4167-ACAC-EFD1777CE8A2 Q28077413-6D26F4EE-6BE9-4BFD-A663-E51387A3B8FA Q28081356-0B361A4D-C07E-48E5-8E1D-400D38E64D7E Q28299271-B198317C-C405-428C-8240-3E7059266915 Q28468689-94A1624B-543F-4182-B291-D2C5E204FDB3 Q28484306-04E23AD5-AF01-4FCA-9DCC-579D57826918 Q28543128-BB4910A8-8FC4-4CD2-8694-9E64951C329C Q28554987-8B9C5389-F574-48C6-8044-2EE5D21D2871

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

http://www.wikidata.org/entity/Q34110066

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

EULAR recommendations for the ...... -modifying antirheumatic drugs

@ast

EULAR recommendations for the ...... -modifying antirheumatic drugs

@en

EULAR recommendations for the ...... -modifying antirheumatic drugs

@en-gb

EULAR recommendations for the ...... -modifying antirheumatic drugs

@nl

type

label

EULAR recommendations for the ...... -modifying antirheumatic drugs

@ast

EULAR recommendations for the ...... -modifying antirheumatic drugs

@en

EULAR recommendations for the ...... -modifying antirheumatic drugs

@en-gb

EULAR recommendations for the ...... -modifying antirheumatic drugs

@nl

prefLabel

EULAR recommendations for the ...... -modifying antirheumatic drugs

@ast

EULAR recommendations for the ...... -modifying antirheumatic drugs

@en

EULAR recommendations for the ...... -modifying antirheumatic drugs

@en-gb

EULAR recommendations for the ...... -modifying antirheumatic drugs

@nl

P1433

Q34110066-88D83E74-7FD2-4DFB-8A68-1EEE597AB549

P1476

Q34110066-CFE73551-5CA4-4485-B8DE-7D106A7EA739

P2093

Q34110066-15AABE29-612C-48AC-AB20-51F156A1ECE8

Q34110066-433ECDAE-5695-4457-91B2-F6535E88F6D4

Q34110066-5FE00C6F-891C-4598-BE41-B8D0CDE6151F

Q34110066-7F914DE2-8026-4129-A9C8-8F3499136E37

Q34110066-87A3A576-68CE-48E4-BD60-E6E0A4022937

Q34110066-8F03C89F-9FAA-4A64-8181-CE99B8BE6877

Q34110066-91D955FF-A126-4D00-A395-1382FE08B3B4

Q34110066-A55F70C6-659F-4838-B214-2FBA3AB8B95B

Q34110066-AA458DF2-AD75-45C7-8067-113342653A52

Q34110066-B5568FF2-FE15-4CFC-8C66-1C9FE82E8AE7

P275

Q34110066-104ABE42-DE45-4771-A98B-899D3FE0AF21

P2860

Q34110066-00ADC9E1-87E7-4D55-A241-2C8587704716

Q34110066-01FBD4B6-1CEE-48DB-822B-B382674A56AD

Q34110066-027106E7-3F63-419F-BD2E-F02BABF3171D

Q34110066-03F753A6-F7CA-4F47-B556-9CD932604C00

Q34110066-0468D5B1-0067-4CBF-98AF-0DFB0BF438E7

Q34110066-0931558C-213D-457F-82A1-99018CD975F2

Q34110066-099426FD-1133-4AAE-9AC8-7B6BE41A3028

Q34110066-12FA9EC6-583E-4E0D-970D-907C5B5F7E67

Q34110066-13BB4ACB-B4F8-4DF5-AB87-04AA0562C4DD

Q34110066-13E30980-EF8E-4DE3-8583-A57F32ECD88D

P304

Q34110066-03654744-0BD4-45A7-850A-2B3D33C517DB

P31

Q34110066-8DF0FE78-82D8-4B44-8F9C-1C8C7A4A41B9

Q34110066-DD833E19-353C-4C7C-8C25-423AEF04AA60

P356

Q34110066-2BB19BBF-70E5-45E1-929F-8433EC18A4C0

P407

Q34110066-CAD55369-A208-4FDF-82B4-36818623D582

P433

Q34110066-6F2474E5-0BAF-4D97-B4CD-81A49F8276E9

P478

Q34110066-46BC5B31-F0C6-4C00-81CB-C163ADB6BF06

P50

Q34110066-25934BDF-F6FE-4D87-9764-904D5BB45CD3

Q34110066-346B2377-9414-42E8-BE93-FC43CE8914ED

Q34110066-3514019B-6B98-4126-ABB5-66FBAB87BC45

Q34110066-3BABE8FD-D916-43CC-9243-F2A24726B25A

Q34110066-6BBC6C40-B0E4-4165-84FC-3FC4B658E7FF

Q34110066-7BB26529-7C99-4511-994C-F4CF43241D8A

Q34110066-A9CE8B4A-9EBB-4788-8F87-0233FD95AF79

Q34110066-AD459904-4B17-4D7B-ACAE-F807B953DC25

Q34110066-B07A27C6-7191-445E-AB6D-B203F3444576

Q34110066-B544ADA9-0EA2-408C-885C-3B1EFFEDB7EF

P5008

Q34110066-1E9B8327-F779-4986-A4C8-9D9894373502

P577

Q34110066-B856213C-8AED-4462-8D4F-B7A1EFA53D78

Q34110066-BE19823C-C0CB-4FEC-B41E-B99BA6267A9C

P5875

Q34110066-184B7FEF-575B-4E0A-BA0A-55B9EDF59B74

P6179

Q34110066-0333A6EC-8231-42DB-B719-2C92B85FC517

P698

Q34110066-937EBC0A-4BDB-49D0-BC41-31B4A79D9DB7

P921

Q34110066-11C66D67-FAE3-4C89-9775-82D289EC6A37

Q34110066-C4B13276-E3CA-4C97-8183-5F650CB82385

P932

Q34110066-F3A39EF0-8896-491C-9C01-7A5BF321319A

P356

ARD.2009.126532

P1433

Annals of the Rheumatic Diseases

P1476

EULAR recommendations for the ...... -modifying antirheumatic drugs

@en

P2093

Angela Zink

http://www.w3.org/2001/XMLSchema#string

Bernard Combe

http://www.w3.org/2001/XMLSchema#string

Cecile Gaujoux-Viala

http://www.w3.org/2001/XMLSchema#string

Daniel Aletaha

http://www.w3.org/2001/XMLSchema#string

David L Scott

http://www.w3.org/2001/XMLSchema#string

Ferdinand C Breedveld

http://www.w3.org/2001/XMLSchema#string

Gerd Burmester

http://www.w3.org/2001/XMLSchema#string

Jackie Nam

http://www.w3.org/2001/XMLSchema#string

Johannes W J W Bijlsma

http://www.w3.org/2001/XMLSchema#string

John Wong

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

Effects of glucocorticoids on radiological progression in rheumatoid arthritis

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.

The definition and measurement of disease modification in inflammatory rheumatic diseases.

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

P304

964-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2009.126532

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Cécile Gaujoux-Viala

Désirée van der Heijde

Robert Landewé

Ronald van Vollenhoven

P5008

P577

2010-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44575352

http://www.w3.org/2001/XMLSchema#string

P6179

1039712973

http://www.w3.org/2001/XMLSchema#string

P698

20444750

http://www.w3.org/2001/XMLSchema#string

P921

rheumatoid arthritis

P932

2935329

http://www.w3.org/2001/XMLSchema#string